Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

BOLERO-2: Practice-Changing Results With Exemestane Plus Everolimus in Advanced Breast Cancer

TOP - February 2012, Vol 5, No 1 published on February 28, 2012 in Breast Cancer

Updated results of the phase 3 BOLERO-2 trial demonstrated that adding everolimus to hormonal therapy extends progression-free survival (PFS) in hormone receptor–positive (HR+) metastatic breast cancer that progressed on hormonal therapy with anastrozole or letrozole. The positive outcomes observed in this study suggest that everolimus plus exemestane will be a new option for postmenopausal metastatic HR+ breast cancer.

First results of this study, called BOLERO-2, were presented in September 2011 at ECCO/ESMO/ESTRO. Updated results with additional follow-up, presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, confirm the PFS benefit of adding everolimus to exemestane in this group of women. Overall survival (OS) data are not yet mature.

“We believe these results underline that everolimus is the first agent to significantly enhance the efficacy of hormonal therapy in patients with HR+ breast cancer. The addition of everolimus in advanced breast cancer could represent a paradigm shift in the management of this patient population,” stated Gabriel N. Hortobagyi, MD, professor of medicine and director of the Multidisciplinary Breast Cancer Research Program at the University of Texas MD Anderson Cancer Center in Houston, Texas

“Endocrine therapy is the treatment of choice for the majority of breast cancers that express the estrogen receptor, which represents about 75% of patients over age 50. The standard is to use multiple endocrine regimens in sequence to get multiple mileage. But the sad truth is that after a few months of suppression of tumor cells on one agent, tumor cells become smarter and resistant and we need to change agents,” Hortobagyi explained.

Everolimus is an mTOR inhibitor. This pathway is activated in hormone-resistant advanced breast cancer. Phase 2 clinical trials of everolimus monotherapy and in combination with endocrine therapy were encouraging in advanced HR+ breast cancer, Hortobagyi explained. Positive results of phase 2 trials with everolimus added to hormonal therapy led to the strategy tested in BOLERO-2, he said.

BOLERO-2 was a prospective, double-blind, placebo-controlled, phase 3 trial. The study population included 724 postmenopausal women with HR+ metastatic breast cancer with disease progression on previous hormonal therapy (ie, resistance). Patients were randomized 2:1 to exemestane plus everolimus (n=485) versus exemestane plus placebo (n=279).

Baseline demographics and disease characteristics were similar between the arms. At baseline, median age was 62 years, 56% had visceral metastases, and 84% had documented benefit from previous endocrine therapy with letrozole or anastrozole (100%), tamoxifen (48%), fulvestrant (16%), and chemotherapy for advanced disease (25%). Sixty percent had excellent performance status. The study population reflects a variety of ethnic groups, he said.

At a median follow-up of 12.5 months, median PFS was 7.4 months for the combination versus 3.2 months for exemestane plus placebo. The percentage of patients who experienced clinical benefit (complete response, partial response, stable disease, amount of pain, and overall benefit of the drug) was almost double in the combination arm: 50.5% for the combination versus 25.5% for exemestane plus placebo.

The combination of exemestane plus everolimus was well tolerated, Hortobagyi told listeners. The most common grade 3 or higher adverse events for the combination versus exemestane plus placebo, respectively, were stomatitis (8% vs 1%), anemia (7% vs 1%), hyperglycemia (5% vs <1%), dyspnea (4% vs 1%), and fatigue (4% vs 1%). Adverse events were manageable with dose delays or dose reductions. 

Quality of life was almost identical in both arms of the study.

Related Items
Trastuzumab Deruxtecan Represents New Standard of Care for Patients with HER2-Low Metastatic Breast Cancer
William King
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Breast Cancer
Olaparib Extends Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
William King
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Breast Cancer
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Charlie Dawson
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Breast Cancer
Cryoablation Appears Safe and Effective in Low-Risk, Early-Stage Breast Cancer
William Ackerman
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in Breast Cancer
Pembrolizumab plus Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
Patricia Stewart
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Breast Cancer
Abemaciclib plus Endocrine Therapy Offers Invasive Disease–Free Survival Benefit in Patients with High-Risk, HR-Positive, Early-Stage Breast Cancer
Patricia Stewart
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Breast Cancer
Breast Cancer Year in Review Introduction
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Last modified: July 22, 2021